Gables Capital Management’s Moderna MRNA Stock Holding History

Gables Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,300	Closed	-$92K	–	364
2020 Q3	$92K	Buy	+1,300	New	+$90.6K	0.06%	157

Other funds holding MRNA

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Gables Capital Management's MRNA Position: Q4 2020 in Review

Gables Capital Management sold out of Moderna (MRNA) in Q4 2020, closing a stake of 1,300 shares — an estimated $92K sold.

Gables Capital Management first reported a position in MRNA in Q3 2020 and held it in 1 quarter. The position peaked at $92K in Q3 2020. 717 funds tracked by Wall St. Rank hold MRNA as of Q4 2020.

Gables Capital Management reported no remaining Moderna position as of Q4 2020 after selling out during the quarter.
Gables Capital Management sold 1,300 Moderna shares in Q4 2020, an estimated $92K.
Gables Capital Management first reported a position in Moderna in Q3 2020 and held it in 1 quarter.
Gables Capital Management's Moderna position peaked at $92K in Q3 2020.
717 funds tracked by Wall St. Rank held Moderna as of Q4 2020.

Based on Gables Capital Management's 13F filing for Q4 2020, filed 3 Feb 2021.